Compound reference · Retatrutide
SOLUTION
PREPARATION
Reconstitution chemistry for 10 mg, 20 mg and 30 mg lyophilized vials at a 10 mg/mL working concentration — what each preparation contains, how much a vial holds, and how long the prepared solution remains characterized.
For research and reference purposes only. Not intended as dosing instructions for human or animal use. Consult a licensed physician before any medical decisions.
Retatrutide is an investigational GLP-1 / GIP / glucagon triple receptor agonist in Lilly’s phase 3 program. It holds no marketing authorization in any jurisdiction, which means there is no approved formulation, no approved concentration, and no established administration protocol outside a controlled trial. Material distributed for research use carries no verified assay of identity, potency, or sterility — every figure below is a calculation about the labeled mass, not a measurement of vial contents.
01 · Notation
The unit that is not a unit.
Volume notation is the largest single source of preparation error in self-mixed peptide work, and it is an arithmetic failure rather than a pharmacological one. A cubic centimetre is a millilitre. It is not a syringe gradation.
On a U-100 insulin syringe, 100 gradations span 1 mL. A figure recorded as “cc” and then read as gradations — or the reverse — is wrong by a factor of one hundred:
2 mg
~200 mg
20 cc is a physically larger volume than any of these preparations contains. Any protocol note, spreadsheet column, or app field carrying this quantity should record units and reference the U-100 scale explicitly. Never let “cc” propagate from one record to the next.
02 · Preparation
One concentration across three vial sizes.
Scaling diluent volume in proportion to labeled mass converges all three vials on an identical working concentration, so a single conversion table describes every preparation:
Aseptic procedure
- Allow the vial to reach room temperature before opening.
- Swab both stoppers — lyophilate and diluent — with fresh alcohol; allow to dry fully.
- Draw the measured diluent volume using a sterile needle. Use a new needle for every puncture.
- Angle the needle so diluent runs down the interior wall of the vial rather than directly onto the cake.
- Do not shake — agitation shears peptide bonds. Roll or swirl until dissolution completes, which may take several minutes.
- A correctly reconstituted solution is clear and colorless. Cloudiness, discoloration, visible particulates, or incomplete dissolution indicate the preparation should be discarded.
- Record the reconstitution date on the vial. Every figure in section 04 is measured from that date.
03 · Solution content
What each draw volume contains.
At a 10 mg/mL reconstitution, a U-100 syringe drawn to the gradations below holds the following quantity of compound in solution:
Literature context. Published phase 2 results (Jastreboff et al., NEJM, 2023) describe trial arms initiating at 1 mg, 2 mg or 4 mg weekly; all but the 1 mg arm escalated in four-week increments to ceilings of 4 mg, 8 mg or 12 mg. Arms that started at 2 mg rather than 4 mg had fewer gastrointestinal events.
Gastrointestinal adverse events in those trials scaled with both absolute quantity and escalation rate, and were the principal cause of participant withdrawal. Trial quantities were administered under titration oversight with scheduled laboratory monitoring; they describe what was studied, not what is appropriate for any individual.
04 · Capacity & characterization window
Where the arithmetic and the chemistry disagree.
Vial capacity is straightforward division. The constraint that actually governs a preparation is narrower — and for the larger vials the two figures diverge sharply:
Bacteriostatic water is preserved with 0.9% benzyl alcohol and is labeled for 28 days following first puncture. Reconstituted peptide degrades on a broadly comparable refrigerated timeline. Past that boundary a preparation carries two compounding unknowns: declining potency, so the quantity drawn no longer matches the quantity in the table above, and a preservative no longer reliably suppressing microbial growth in a repeatedly punctured vial.
At draw volumes in the range the trials describe, a 30 mg vial holds close to four times what its characterization window covers. Dividing the lyophilate across smaller diluent volumes does not extend this — the interval runs from reconstitution regardless of how much water was added. The only variables that genuinely shorten time-in-use are a smaller vial or a larger draw, and draw quantity is not a parameter to select for the convenience of vial arithmetic.
Storage
- Pre-reconstitution: lyophilized powder, refrigerated, protected from light.
- Post-reconstitution: 2–8 °C. Do not freeze — ice crystal formation damages peptide structure.
- Minimize time at room temperature and exposure to direct light.
- Swab the stopper before every draw; new sterile needle every time.
- Discard on any change in clarity, color, or the appearance of particulates.
05 · Reported effects
What the trial record describes.
Gastrointestinal effects dominate the published adverse-event profile: nausea, vomiting, diarrhea, constipation, and early satiety. Dose-dependent increases in resting heart rate were also recorded. Because this receptor class suppresses appetite substantially, dehydration and inadequate protein intake are documented secondary risks that compound the primary gastrointestinal burden.
Presentations that warrant prompt clinical assessment in the literature include severe or persistent abdominal pain — particularly pain radiating to the back, a recognized presentation of pancreatitis — persistent vomiting or signs of dehydration, and symptoms consistent with significant hypoglycemia.
A clinician assessing any of the above needs an accurate account of what was administered and in what quantity. Withholding that information impairs diagnosis; it is not a precondition of receiving care.
06 · Limits of this reference
What this document cannot establish.
Whether the vial contains retatrutide, and at the labeled mass. Every calculation here is downstream of an assumption no reference sheet can verify.
Non-pharmaceutical fill carries endotoxin and contamination risk that aseptic handling at the point of preparation cannot correct for.
Interaction with medical history, concurrent medications, and monitoring requirements — the oversight a trial protocol supplies and self-administration does not.
Phase 3 evaluation is incomplete. Long-term safety, durability of effect, and the full interaction profile are not yet established in the published record.
Educational reference only. Peptide Cortex describes how compounds are studied — it does not diagnose, treat, prescribe, or provide personal dosing instructions. Verify all figures against primary literature and a licensed physician.